A practical reference on fatty diacid chain: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-09-17 and is reviewed periodically as new material appears.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
| Property | Value | Notes |
|---|---|---|
| Molecular class | 31-amino-acid peptide | Modified glucagon-like peptide-1 analogue |
| Molecular mass | approximately 4114 Da | Calculated for the free peptide backbone |
| Appearance | white to off-white powder | Typical of purified lyophilised peptide batches |
| Solubility class | freely soluble in water | Aqueous solubility improves at slightly alkaline pH |
| Typical storage | -20 degrees Celsius, dry, dark | Protect from repeated freeze-thaw cycles |
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
Due to a uterine first-pass effect and markedly higher uterine progesterone levels than with other routes, 45 mg/day vaginal progesterone, a dosage that achieves circulating progesterone levels of only 1 to 5 ng/mL, provides complete endometrial transformation. Conversely, intranasal administration of progesterone achieving progesterone levels of 2 to 5 ng/mL was ineffective. Transdermal progesterone achieves very low progesterone levels and is considered to be ineffective for endometrial protection. The endometrial transformation dosage of oral micronized progesterone in women has been listed as 200 to 300 mg/day or 4,200 mg total per cycle. However, a clinical study found that 300 mg/day oral micronized progesterone was insufficient for full endometrial transformation. Similarly, 600 to 1,000 mg/day oral micronized progesterone has been reported to be ineffective for achieving complete endometrial transformation. Despite inadequate endometrial transformation with oral progesterone, continuous 100 mg/day oral micronized progesterone or cyclic 200 mg/day oral micronized progesterone is effective for protection of the endometrium against estrogen-induced endometrial hyperplasia. On the other hand, and in contrast to progestins, typical clinical doses of oral micronized progesterone have been associated with failure to prevent increased endometrial cancer risk caused by estrogen therapy.
Durand sold the patent to Bryan Donkin, who spent two years perfecting the method. Canned food subsequently began to be issued to the Royal Navy. The reason for lack of spoilage was unknown at the time, since it would be until the 1860s before Louis Pasteur demonstrated the role of microbes in food spoilage and developed pasteurization. The Crimean War saw issues with supplying soldiers in battle. In the British Army, rations were regularly halved, and many soldiers developed scurvy, to the point that the hospital in Scutari received more soldiers for scurvy than battle wounds. During the American Civil War, the food and rations of the Union Army and the Confederate States Army were meant to be mostly the same—meat, cornmeal, vegetables, vinegar, molasses, and hardtack—but supply issues plagued the Confederates as the war continued, forcing them to live off the land. The standard Union Army ration was roughly three-quarters pound (340 g) of meat, one pound (450 g) of flour or cornmeal, vegetables, vinegar, and molasses. To ensure that food lasted longer, rations often came in the form of hardtack biscuits, salted meat, and dehydrated vegetables. During campaigns, particularly as Union troops entered the south, seasonal fruits and vegetables were pillaged from farms and orchards. Both the Union and Confederate armies relied on lakes and streams for their water.
=== Enhanced oil recovery and carbon capture and storage === Supercritical carbon dioxide is used to enhance oil recovery in mature oil fields. At the same time, there is the possibility of using "clean coal technology" to combine enhanced recovery methods with carbon sequestration. The CO2 is separated from other flue gases, compressed to the supercritical state, and injected into geological storage, possibly into existing oil fields to improve yields. At present, only schemes isolating fossil CO2 from natural gas actually use carbon storage, (e.g., Sleipner gas field), but there are many plans for future CCS schemes involving pre- or post-combustion CO2. There is also the possibility to reduce the amount of CO2 in the atmosphere by using biomass to generate power and sequestering the CO2 produced.
As in the case of women, men are more prone to develop an eating disorder if their occupation or sport emphasizes having a slim physique or lighter weight, like modeling, dancing, horse racing, wrestling, and gymnastics. Hormonal changes may also be observed in males with anorexia nervosa, with marked changes in their serum testosterone, luteinizing hormone, and follicle stimulating hormone. Such extreme endocrine disturbances can potentially result in infertility. Anorexic men are sometimes colloquially referred to as manorexic or as having bigorexia.
Berhanu Kebede (born 11 April 1956) is an Ethiopian diplomat who is the current chief of staff at RJMEC – Reconstituted Joint Monitoring and Evaluation Commission for the Agreement on the Resolution of the Conflict in the Republic of South Sudan.
Sources: en.wikipedia.org
== Etymology of anesthesia == In ancient Greek texts, such as the Hippocratic Corpus and the dialogue Timaeus, the term ἀναισθησία (anaisthēsíā) is used, which translates to "without sensation". This term is derived from the prefix ἀν- (an-), meaning "without", and αἴσθησις (aisthēsis), which means "sensation". The concept of anaisthēsia is significant in understanding the historical foundations of anesthesia and its relevance in medical practices. In 1679, Steven Blankaart published Lexicon medicum graeco-latinum with the Latin term anaisthesia. In 1684, an English translation appeared titled A Physical Dictionary, with anesthesia defined as a "defect of sensation, as in paralytic and blasted persons". Subsequently, the term and variant spellings like anæsthesia are used in medical literature signifying "insensibility". In 1846, in a letter, Oliver Wendell Holmes proposed the term anesthesia to be used for the state induced by an agent and anesthetic for the agent itself. Holmes motivates this with earlier uses of anesthesia in medical literature to mean "insensibility", particularly to "objects of touch".
== Activators and inhibitors == FFAR2 and FFR3 are activated primarily by short-chain fatty acids (SCFAs) that are 2 to 6 carbons in length (see length of fatty acids). In humans, acetic acid, which has 2 carbon atoms, is a strong activator of FFAR2 but very weak activator of FFAR3; propionic and butyric acids, which have 3 and 4 carbons, respectively, are strong activators of both FFAR2 and FFAR3; pentanoic acid, which has 5 carbon atoms, is a weak activator of FFAR2 but strong activator of FFAR3; and hexanoic acid, which has 6 carbon atoms, is a weak activator of FFAR3 but its effect on FFAR2 has not been reported. More recently, the ketone body fatty acid, acetoacetic acid, while not classified as a SCFA, has been shown to activate FFAR2 with a potency similar to acetic and propionic acids. Many drugs have been developed that bind to and regulate FFAR2's activity. 1) MOMBA, Sorbate, and Compound 1 are orthostatic agonists, i.e., they bind to the same site as SCFAs to activate FFAR2. 2) Compound 58 and AZ1729 are positive allosteric agonists, i.e., they bind to FFAR2 at a site different than the orthostatic binding site and do not by themselves alter FFAR2 activity but enhance the ability of SCFAs and other FFAR2 orthostatic agonists to activate FFAR2. 3) CATPB and BTI-A-404 are reverse agonists, i.e., they bind to the same site as SCFAs but induce a response opposite to that induced by SCFAs.4) 4-CMTB and TUG-1375 are classified as FFAR2 agonists but studies are needed to define their binding sites on FFAR2.
== Cleaning up oil spills == The U.S. Environmental Protection Agency (EPA) documents more than ten thousand oil spills per year. Conventionally, biological, dispersing, and gelling agents are deployed to remedy oil spills. Although, these methods have been used for decades, none of these techniques can retrieve the irreplaceable lost oil. However, nanowires can not only swiftly clean up oil spills but also recover as much oil as possible. These nanowires form a mesh that absorbs up to twenty times its weight in hydrophobic liquids while rejecting water with its water repelling coating. Since the potassium manganese oxide is very stable even at high temperatures, the oil can be boiled off the nanowires and both the oil and the nanowires can then be reused. In 2005, Hurricane Katrina damaged or destroyed more than thirty oil platforms and nine refineries. The Interface Science Corporation successfully launched a new oil remediation and recovery application, which used the water repelling nanowires to clean up the oil spilled by the damaged oil platforms and refineries.
In order to prevent Toll-like receptor pathway activation, the cytosine nucleobases within the aptamer can be methylated. Nevertheless, despite these potential solutions to reduced in vivo efficacy, it is possible that chemically modifying the aptamer may weaken its binding affinity towards its target.
Emmanuel Philibert, also known under the nickname of Iron Head (Testa 'd Fer), made Turin the capital of the Duchy of Savoy in 1563. Piazza Reale (named Piazza San Carlo today) and Via Nuova (current Via Roma) were added along with the first enlargement of the walls, in the first half of the 17th century; in the same period the Palazzo Reale (Royal Palace of Turin) was also built. In the second half of that century, a second enlargement of the walls was planned and executed, with the building of the arcaded Via Po, connecting Piazza Castello with the bridge on the Po through the regular street grid. In 1706, during the Battle of Turin, the French besieged the city for 117 days without conquering it. By the Treaty of Utrecht the Duke of Savoy acquired Sicily, soon traded for Sardinia, and part of the former Duchy of Milan, and obtained the title of King of Sardinia; thus Turin became the capital of a European kingdom. The architect Filippo Juvarra began a major redesign of the city; Turin had about 90,000 inhabitants at the time.
Sources: en.wikipedia.org
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.
No. It shares high sequence identity but carries non-natural modifications that alter its stability and clearance. The naturally occurring hormone is broken down within minutes, while the synthetic analogue circulates far longer.
Attachment to serum albumin reduces renal filtration of the peptide and shields it from enzymatic breakdown. The consequence is a much longer interval between administrations than unmodified peptides allow. The precise contribution of binding affinity to overall duration is still being quantified.
Ice formation concentrates solutes and can mechanically stress the peptide or damage the delivery device. Thawing afterwards may leave aggregates that are not visible to the eye. Refrigeration keeps the solution above its freezing point while slowing chemical degradation.